MA-IBASIS
2.3.2023 16:19:44 CET | Business Wire | Press release
iBASIS, the leading provider of communications solutions for operators and digital players worldwide, and Sequans Communications S.A. (NYSE: SQNS), a leading developer and provider of 5G/4G chips and modules, today announced that Actility, a leading provider of IoT connectivity platform, has chosen iBASIS and Sequans to roll out programmable cellular IoT solutions with eSIM and iSIM.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230227005808/en/
Actility had previously worked closely with iBASIS to enable roaming between private unlicensed networks powered by ThingPark EPC Connector and public networks, using Simfony’s CMP platform, now fully integrated with iBASIS’ Global Access for Things™ IoT portfolio. The longstanding partnership between iBASIS and Sequans has produced several successful proofs of concept.
The new ultra-low-power multi-technology trackers of Abeeway, a fully owned Actility subsidiary, will benefit from Sequans Monarch 2 LTE-M/NB-IoT platform with integrated iSIM and the connectivity profile provided by iBASIS, allowing the device to connect to cellular networks worldwide. Actility will also benefit from Sequans Monarch 2 being the first iSIM implementation that has achieved common criteria EAL5+ certification, allowing the use of iBASIS’ intelligent profile selection technology with remote update using multiple Tier-1 operator profiles as provided for eSIM.
iSIM is fully integrated in the cellular modem and microcontroller unit on a single system on chip (SoC). It relies on the existing eSIM infrastructure accessing 2/3/4/5G networks using the global footprint of iBASIS. iSIM is considered to be the future of connectivity technology for many IoT deployments.
An important step forward in the IoT industry, iSIM will positively influence device design in the areas of space optimization, and reduction of energy and power consumption. By eliminating the need for a separate SIM chip, iSIM will provide the customer with a more streamlined supply chain experience when manufacturing a device using cellular connectivity. The entire supply chain will benefit from the reduction of materials which will lead to lower costs for manufacturers.
According to Counterpoint Research, beyond 2027 iSIM is projected to take over as the dominant SIM form factor, with the shipments of iSIM-capable devices poised to scale to 7 billion units between 2021 and 2030.
With the iBASIS Global Access for Things™ industry-leading coverage, eSIM/iSIM enables enterprises to easily adopt a single global, remotely programmable SIM that provides mobile data connectivity to smart devices all over the world.
“After recent collaboration with iBASIS, adding iBASIS connectivity on our Monarch 2 module with eSIM, and having fully tested the global connectivity on iSIM, we are now advancing into an integrated production phase driven by a customer need,” said Louis Chuang, EVP of Sequans’ Massive IoT Business Unit. “We are thrilled to reach this important milestone with iBASIS whereby we can offer customers a powerful iSIM capability, along with low power consumption, cost-efficiency, and GNSS support.”
“After being recognized as a leader in the cellular IoT connectivity market with eSIMs, we are delighted to implement iSIM technology together with our trusted partner Sequans,” said Ajay Joseph, CEO IoT & CTO, iBASIS. “After many years of research and development, while deploying iSIM technology in trial environments, it is a great achievement by our teams. This once again underlines that iBASIS is a frontrunner and truly lives by its motto: ‘Be there first’. We strongly believe that iSIM will become a dominant factor within the IoT industry and I am proud to see that we are now able to provide our longstanding customer Actility with our proven IoT connectivity on iSIM.”
“Our focus is ultra-low-power industrial IoT connectivity. The new cellular trackers of our subsidiary Abeeway leverage LTE-M and NB-IoT, and our ThingPark EPC Connector for unlicensed private cellular networks (such as CBRS) rely on recent 3GPP slicing technologies,” said Olivier Hersent, CEO of Actility. “We needed cutting edge partners to support reliable LTE-M connections with PSM/eDRX options in permanent roaming as well as iSIMs: after extensive testing we selected Sequans for their ability to support iSIMs and because 100 percent of their software stack is developed in-house, and iBASIS for their ability to support complex integration and their focus on quality, based on proactive testing. Together, I think we form the dream team for industrial low-power IoT.”
To find out more, visit iBASIS in Hall 2, MR 2A6 and 2A8, and Sequans in Hall 5, Stand 5H40, at Mobile World Congress from February 27 to March 2 in Barcelona.
ABOUT iBASIS
iBASIS is the leading communications solutions provider enabling operators and digital players worldwide to perform and transform. Powered by Tofane Global, iBASIS is the first independent communications specialist, ranking third largest global wholesale voice operator, Top 3 LTE IPX vendor with 700+ LTE destinations, and a leading Carrier Cloud Communications player and IoT solution provider. iBASIS provides the end-to-end Global Access for Things™ connectivity solution, delivering single source cellular IoT access (LTE, LTE-M and NB-IoT) worldwide provisioned through GSMA-standard eSIM/eUICC technology. iBASIS today serves 1,000+ customers across 26 offices worldwide. For more information, please visit iBASIS.com.
ABOUT SEQUANS
Sequans Communications S.A. (NYSE: SQNS) is a leading developer and supplier of cellular IoT connectivity solutions, providing chips and modules for 5G/4G massive and broadband IoT. For 5G/4G massive IoT applications, Sequans provides a comprehensive product portfolio based on its flagship Monarch LTE-M/NB-IoT and Calliope Cat 1 chip platforms, featuring industry-leading low power consumption, a large set of integrated functionalities, and global deployment capability. For 5G/4G broadband IoT applications, Sequans offers a product portfolio based on its Cassiopeia Cat 4/Cat 6 4G and high-end Taurus 5G chip platforms, optimized for low-cost residential, enterprise, and industrial applications. Founded in 2003, Sequans is based in Paris, France with additional offices in the United States, United Kingdom, Israel, Hong Kong, Singapore, Finland, Taiwan, South Korea, and China. Visit Sequans online at www.sequans.com, and follow us on Twitter and LinkedIn.
ABOUT ACTILITY
Actility is the world leader in Low-Power Wide-Area Networks (LPWAN) industrial-grade connectivity solutions for the Internet of Things. Actility provides its ThingPark™ platform and network technology to deploy, operate and maintain public and private wireless IoT networks within a unified, scalable and versatile network infrastructure. The vast majority of nationwide LPWAN network service providers and hundreds of enterprises trust ThingPark™ all over the world. Through its subsidiary Abeeway, Actility also provides patented ultra-low power tracking solutions. ThingPark Market offers the largest selection of interoperable IoT gateways, devices and applications to simplify and accelerate deployment of numerous use cases. Contact us here: https://www.actility.com/contact
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230227005808/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Merz Therapeutics Presents New Phase 2 PaiNT Data in Peripheral Neuropathic Pain at IASP 202626.10.2026 08:00:00 CET | Press release
Clinical and preclinical presentations reflect the company’s ongoing exploration of peripheral neuropathic pain Merz Therapeutics, a leading player in neurology-focused specialty pharma, today announced the presentation of new clinical and translational research in peripheral neuropathic pain (PNP) at the International Association for the Study of Pain (IASP) 2026 World Congress in Bangkok, Thailand, taking place from 26 to 30 October. The research spans new Phase 2 findings on incobotulinumtoxinA in postherpetic neuralgia (PHN) and post-surgical/post-traumatic neuropathic pain (PS/PTNP), as well as preclinical studies exploring potential biological mechanisms involved in effects of incobotulinumtoxinA on PNP models, highlighting Merz Therapeutics’ growing presence in neuropathic pain. In the PHN population of the Phase 2 PaiNT trial, results over 20 weeks favored incobotulinumtoxinA versus placebo treatment. In an exploratory analysis of average daily pain (ADP) intensity, the greates
Andersen Consulting tilføjer samarbejdsfirmaet TechSparq25.10.2026 06:09:00 CET | Pressemeddelelse
Andersen Consulting udvider sine kompetencer inden for teknologi og forretningstransformation gennem en samarbejdsaftale med TechSparq, en amerikansk virksomhed, der kombinerer strategi, commerce engineering og ai med praktisk implementering. TechSparq er et digitalt konsulenthus, der tilbyder strategi- og rådgivningstjenester, commerce engineering samt tjenester inden for ai og agentbaseret handel til virksomheder inden for detailhandel og forbrugsgoder, luksus og mode samt e-handel og direkte salg til forbrugere. Virksomheden har hovedkontor i Oregon og kombinerer strategisk planlægning med praktisk implementering for at hjælpe kunderne med at udvikle deres digitale initiativer, kundeoplevelse og driftsmodeller. "Vi etablerede vores virksomhed for at bygge bro mellem dem, der udvikler strategien, og dem, der har ansvaret for at føre den ud i livet," udtalte Dedrick Boyd, stifter af og administrerende direktør for TechSparq. "Vores samarbejde med Andersen Consulting giver os mulighed
BeOne Presents Compelling Data in Hard-to-Treat Liver and Lung Cancers at ESMO 202624.10.2026 10:15:00 CEST | Press release
Potential first-in-class GPC3 x 4-1BB bispecific achieves a 36% confirmed response rate at Phase 3 dose and favorable safety profile in heavily pretreated liver cancerBrain-penetrant PRMT5 inhibitor shows promising antitumor and CNS activity in the largest publicly shared MTAP-deficient datasetFirst clinical data of CEA-targeting ADC demonstrates encouraging and sustained responses in CEAhigh NSCLC BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data from multiple differentiated investigational medicines across its priority solid tumor disease areas at the European Society for Medical Oncology (ESMO) Congress 2026 (October 23–27, Madrid). The presentations span gastrointestinal, lung, and breast cancers, and reflect the growing momentum of BeOne’s solid tumor franchise. Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “At ESMO, we are showing how our strategy of matching the right modality to dise
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press release
- Vertex is on track for the U.S. FDA Prescription Drug User Fee Act (PDUFA) date of November 30 for potential accelerated approval of povetacicept –- Data published in NEJM and presented at ASN highlight povetacicept’s unique trifecta of efficacy, favorable safety, and the simplicity of dosing at-home every 4 weeks with a low-volume autoinjector –- Data presented at ASN include a qualitative study examining patient perspectives on current and emerging IgAN therapies, showing that 96% of participants preferred an autoinjector over a prefilled syringe, and 80% of participants preferred dosing every 4 weeks versus weekly dosing - - New clinical studies of povetacicept underway including a study evaluating patient experience on povetacicept administered via autoinjector - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Soc
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press release
New data from HERIZON-GEA-01 Phase 3 trial show 36-month overall survival of nearly 40% with TEVIMBRA plus ZIIHERA and chemotherapy, and median OS reaching 27 monthsTEVIMBRA-containing arm was associated with a four-month longer median OS compared with ZIIHERA plus chemotherapy BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne,
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom